USPTO issued Patent US12590301B2 to Thrombolytic Science, LLC for methods of thrombolytic therapy combining sequential administration of human tPA and mutant human pro-urokinase. The 16 claims cover therapeutic applications for human subjects presenting symptoms of potential stroke or acute myocardial infarction. The patent was filed on December 30, 2021, as Application No. 17566077.

Pharmaceutical companies developing thrombolytic therapies should review this patent to assess freedom-to-operate for competing treatments. Healthcare providers and clinical investigators conducting related research should verify that their activities do not infringe on the claimed methods. The patent provides intellectual property protection but does not impose regulatory compliance obligations.